Skip to main content
. 2020 Oct 22;19:184. doi: 10.1186/s12933-020-01160-y

Table 1.

Patient characteristics

Controls T2DM without LGE T2DM with ischemic LGEa T2DM with non-ischemic LGE P valueb P valuec
Number 25 207 32 25
Age, years 57 IQR50–64 59 IQR50–67 64 IQR56–69.5 64 IQR57–72 0.008 0.06
Body mass index, kg/m2 25.1 ± 3.3 31.0 ± 4.7 31.9 ± 4.9 30.8 ± 3.7  < 0.001 0.8
Male sex (n,%) 17 (68) 140 (68) 24 (75) 23 (92) 0.08
Diabetes duration, years 12.2 ± 8.2 12.4 ± 8.0 15.4 ± 9.0 0.20
Systolic blood pressure, mmHg 133 ± 16 134 ± 18 142 ± 21 142 ± 14 0.04 0.06
Diastolic blood pressure, mmHg 81 ± 10 81 ± 9 82 ± 13 81 ± 9 0.98
Active or former smoker (n,%) 11 (44) 135 (65) 29 (91) 16 (64) 0.003 1.0
History of ischemic heart disease (n,%) 15 (7) 26 (81) 3 (12)  < 0.001 0.4
History of hypertension (n,%) 4 (25) 137 (66) 28 (87.5) 21 (84)  < 0.001 0.07
NYHA class II/III (n,%) 41 (20) 8 (25) 6 (24) 0.82
Insulin treatment (n,%) 120 (58) 18 (56) 18 (72) 0.38
HbA1c, mmol/mol 35 ± 3 62 ± 15 62 ± 16 64 ± 14  < 0.001 0.65
Creatinine, µmol/L 86 IQR67–89 71 IQR59–86 75 IQR65–87 74 IQR65–90 0.052
LDL cholesterol, mmol/L 3.0 IQR2.2–3.7 1.9 IQR1.5–2.5 1.4 IQR1.2–2.0 1.8 IQR1.3–2.8 0.0001 0.68
High–sensitive CRP, mg/L 2.1 IQR1.0–4.3 2.3 IQR1.0–4.0 2.5 IQR1.3–5.2 0.57
Pro-BNP, µmol/L 5.9 IQR5.9–10.1 8.0 IQR5.9–17.3 8.9 IQR5.9–19.7a 0.02 0.02
High-sensitive TNT, ng/L 13.0 IQR13.0–14.6 13.6 IQR13.0–17.6 15.6 IQR13.0–26.1a 0.008 0.0007
Pro-ANP, µmol/L 57 IQR42–90 108 IQR47–174 75.5 IQR48–127 0.01 0.1

Data presented as median and interquartile range (IQR) or as nominal values with percentages in parentheses

aIncluding three patients with both ischemic and non-ischemic lesions

bComparison between all three groups as appropriate

cComparison between T2DM patients with non-ischemic LGE vs. T2DM patients without LGE